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Purpose: To study the effect of inhaled corticosteroid (ICS) on bone mineral density (BMD)
in an observational longitudinal study.
Methods: In 1995–97, as part of the Nord-Trøndelag Health Study, Norway, 10,941 subjects
aged 20 yr or more, either reporting asthma diagnosis/asthma-related symptoms or
randomly selected, were interviewed, underwent spirometry and had their forearm BMD
assessed. Among these, 4705 persons were invited to follow-up interview and bone
densitometry in 2001; a total of 2848 subjects were eligible for analyses.
Results: Use of corticosteroids for respiratory diseases was reported by 1262 subjects, and
528 subjects had used ICS at both baseline and follow-up. The yearly loss of adjusted
forearm distal BMD was higher in those reporting use of ICS at both baseline and follow-up
compared to subjects without respiratory symptoms. In women the figures were 3.14
versus 2.26mg/cm2, whilst in men they were 3.76 versus 1.92mg/cm2 (both po0.01). No
significant association was found between loss of BMD and neither daily dose nor duration
of ICS use. Reduced lung function (forced expiratory flow in 1 s) was an independent risk
factor for increased bone loss in both sexes.
Conclusions: ICS users had greater bone loss at the forearm compared to ICS naive persons,
but no significant dose–response effect between ICS and BMD was found. Residual confounding
by disease severity cannot be ruled out, but even in case of an ICS causal effect, this should
have minor clinical significance in most patients using low to moderate doses of ICS.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Inhaled steroids and forearm bone mineral density 1745Introduction 50–59 and 65–69 yr reporting respiratory symptoms (becauseInhaled corticosteroids (ICS) are recommended and widely
used in the treatment of bronchial asthma1 and the more
severe stages of chronic obstructive pulmonary disease
(COPD).2 Oral corticosteroids (OCS) reduce bone mineral
density (BMD) and increase fracture risk,3 whilst conflicting
results have been reported regarding corresponding adverse
effects by ICS.4–6 As there does not seem to be a threshold
dose below which no bone loss occurs,7 a dose–response
relationship also between ICS and bone loss might be
plausible. Even if the preferred site of measurement has
been the hip and spine, one standard deviation (SD)
decrease in forearm BMD has been associated with
80–110% higher risk of hip fracture, and 40–50% higher risk
of fracture at any site.8 Few population-based studies have
focused on effects of actual use of ICS on bone, and the
present aim was to study corticosteroid (CS) effects over
time on bone, and to reveal any dose–response relationship
between ICS use and bone loss.Methods
Participants
In 1995–97, all residents aged at least 20 yr of Nord-
Trøndelag County, Norway, were invited to the Nord-
Trøndelag Health Study (HUNT 2).9 A sub-study, the
Bronchial Obstruction in Nord-Trøndelag Study (BONT),
performed a structured interview, forearm bone densito-
metry and spirometry of 10,941 among all 65,225 HUNT 2
participants. These were selected due to positive answers to
questions on having or having had asthma, asthma-related
symptoms or use of asthma medication (n ¼ 8150), or
representing a randomly selected 5% sample (n ¼ 2791).
In a follow-up study in 2001, the BONT Study invited the
randomly selected sample, everyone having reported ever
use of ICS, and an additional random sample of women aged(II) Respiratory  
symptoms, 
  but never use  
of  ICS or OCS
Baseline (BL) 
N=4,705 
n
n=53n=40 
Follow-up (FU)
N=2,848 
n=1,089 
n=454 
51.2 % 
n=1,132 
65.0 % 
n=1,884 
Measurement 
(I) No respiratory 
 symptoms 
Figure 1 Number of participants at baseline (1995–97) and at follow
use of inhaled corticosteroids (ICS)/oral corticosteroids (OCS). At fo
category.of possible confounding by use of estrogen, n ¼ 633).
Subjects reporting rheumatoid arthritis (n ¼ 192) or ever
use of oral corticosteroids (OCS) because of non-respiratory
disease (n ¼ 273) at baseline were not invited. The follow-
up study included questionnaire/interview and forearm
bone densitometry.Measurements
During the data collection in 1995–97, two teams visited all
24 municipalities of the county, whilst at follow-up the
assessments were centralised to 15 municipalities.
The non-dominant forearm distal and ultradistal BMD was
assessed with the single-energy X-ray absorptiometry
technique with three Osteometer DTX100.10 Measurement
sites were manually controlled and corrected, and all
measurements were standardised by equipment-specific
correction factors estimated by repeated measurements of
the European Forearm Phantom (QRM GmbH, Moehrendorf,
Germany) consisting of three hydroxyapatite bone imita-
tions with different densities. Flow volume spirometry was
performed at baseline according to current recommenda-
tions with Masterscope spirometers.11 The subjects an-
swered questions on respiratory symptoms and use of
asthma medication. Type and dose of ICS was indicated on
coloured pictures of all devices available in Norway prior to
follow-up. The subjects were asked to specify the daily dose
of ICS actually taken during the last week.10Statistical analyses
The participants were put into three main categories, (I)
those without respiratory symptoms, (II) those with respira-
tory symptoms without prior use of CS and (III) those having
used CS for respiratory disease (Fig. 1). The two latter
categories included both subjects with asthma and COPD.=145 
 
a) No CS at BL or FU:  n=368
b) ICS at BL only: n=153  
c) ICS at BL and FU: n=528   
d) ICS at FU only: n=196  
e) Only OCS: n= 17  
n=1,732 
n=1,262 
61.4 % 
(III) Previous/ 
current use 
of ICS or OCS for
respiratory disease 
-up (2001) according to self-reported respiratory symptoms and
llow-up, participation percentage is given according to original
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A. Langhammer et al.1746Differences in baseline characteristics between partici-
pants and those lost to follow-up were assessed using
t-tests for continuous variables and w2-tests for categoric
variables.
Multiple linear regression models (MLR) for yearly loss in
BMD (distal and ultradistal) during follow-up, stratified by
sex, were tested with independent variables as (a) baseline
variables: age, weight, and forced expiratory flow in 1 s in
percent predicted (FEV1% predicted), (b) change in weight
during follow-up, and (c) follow-up data on smoking status
(current smoker or not, pack-years), use of estrogen, years
since menopause, and physical activity in addition to CS use.
The covariates contributing significantly were included in
the analyses, these were age, FEV1% predicted, current
smoker or not, and in women use of hormone replacement
therapy. Analyses including log current dose, log mean dose
reported at baseline and follow-up, duration of ICS use, and
estimated categories of cumulative dose were restricted to
those having used ICS at both measurements.
Changes in BMD were analysed by analysis of variance
stratified by sex including covariates derived from the MLR
model. According to CS use the subjects were categorised
into seven mutually exclusive categories and entered as a
seven-level factor in the analyses (Fig. 1). The levels were:
(I) no respiratory symptoms and no previous use of CS, (II)
respiratory symptoms but no previous use of CS, (III a)
previous use of ICS, but not current use at baseline or
follow-up, (III b) current use of ICS at baseline only, (III c)
current use of ICS at follow-up only, (III d) current use of ICS
at both baseline and follow-up, and (III e) use of OCS only.
The analyses were also performed after stratification by
age groups, use of OCS or not, dose and duration of use
categories for ICS, and in women, use of hormone replace-
ment therapy (estrogen) or not. Analyses were also
performed excluding those having reported fractures at
the wrist, but this did not influence the results. As the
dependent variable was yearly change in BMD and this is an
observational study, baseline BMD was not included as
covariates in the final analyses. However, even if baseline
BMD was a highly significant covariate, inclusion of this in
the analyses did not influence the main results.
The main results are reported from models including
subjects of all levels. Differences between levels were
tested both using level I and level II as references. In
analyses using level II as reference, subjects without
respiratory symptoms were excluded.
Standardisation to beclomethasone diproprionate (BDP)
equivalent doses was not performed as many subjects had
used more than one ICS type and there was no consensus as
to the relative systemic effects of the different types.12
Physical activity was assessed by two questions: (a) hours
per week with light activity (no sweating or breathlessness)
and (b) hours per week with hard physical activity (sweating
and breathlessness), both with four alternatives graded
from none to X3 h).
Missing data on estrogen use were recoded as never use
(n ¼ 165), and users of bisphosphonates (n ¼ 7) were not
excluded from the analyses, as the use did not influence the
results. Data on use of other medications with potential
effects on BMD were not available. The Statistical Package
for the Social Sciences version 12.0 was used, and
significance level set to 0.05 (two sided).Ethics
The study was approved by the Regional Committee in
Medical Research and the Norwegian Data Inspectorate. All
participants signed informed consent.
Results
Participation
The mean time from baseline measurement to follow-up was
4.6 yr (range 3.4–5.5 yr). Among subjects participating at
baseline, 65% without respiratory symptoms, 51% with
respiratory symptoms without use of CS, and 61% with
previous or current use of CS for respiratory diseases met to
the follow-up measurements (Fig. 1). Among CS-naı¨ve
subjects at baseline, 198 subjects reported having started
with ICS during follow-up.
Table 1 shows baseline characteristics of subjects who
were lost to follow-up and those participating at both times.
Among women, current smoking, respiratory symptoms and
diseases were more common in those participating only at
baseline, and this group also had lower FEV1% predicted and
BMD (all po0.05). Among men, except for younger age and
lower score on physical activity (both po0.05) for those
being lost to follow-up, there were only minor differences.
Use of inhaled CS (Table 2)
Among 528 persons currently using ICS both at baseline and
at follow up, 23% used ICS dose 4800 mg at follow-up, and
91% had used ICS for 5 years or more.
The three different types of ICS used were BDP
(GlaxoSmithKline), budesonide (BUD, AstraZeneca), and
fluticasone propionate (FP, GlaxoSmithKline). More than
80% were using powder inhalers at both measurements. At
follow-up, 58% of FP users reported current use of fixed
combination of FP and salmeterol, and some 30% of ICS users
at follow-up had used two ICS types during the last 6
months.
Characteristics of participants
Those using ICS at follow-up were older, had lower lung
function, higher smoke burden, and lower score on physical
activity compared to those with previous or no use of ICS
(Table 3). Baseline smoke burden (pack-years) and level of
physical activity influenced baseline BMD,10 but did not
significantly influence change in BMD.
Associations
In unadjusted analyses, current use of ICS at follow-up was
associated with increased yearly loss of BMD, both in those
using ICS at follow-up only, and in those using ICS at both
baseline and follow-up, when those without respiratory
symptoms were used as reference (Fig. 2). In women
significant associations were found for distal BMD, whilst in
men these were also found for ultradistal BMD.
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Table 1 Baseline characteristics of 4705 persons invited to follow-up shown as mean (SD) or prevalence (%), according to
participation only at baseline ( ¼ lost to follow-up, n ¼ 1857) and at follow-up (n ¼ 2848), stratified by sex.
Characteristic Lost to follow-up Met to follow-up
Women Men Women Men
n ¼ 1079 n ¼ 778 n ¼ 1752 n ¼ 1096
Mean age in years (SD) 50.9 (17.1) 48.3 (17.7) 51.3 (13.9) 53.1 (14.8)b
Mean height in cm (SD) 163.3 (6.5) 177.4 (7.2) 164.0 (6.0) 176.8 (6.6)
Mean weight in kg (SD) 72.1 (14.6) 83.3 (13.1) 72.4 (13.1) 83.8 (12.2)
Mean FEV1% predicted (SD) 89.4 (19.9) 87.1 (20.8) 92.0 (18.6)
b 88.3 (20.9)
Mean score physical activity (SD) 3.6 (2.2) 3.9 (2.2) 3.8 (2.0) 4.2 (2.1)b
Mean pack-years cigarettes (SD) 6.7 (10.3)b 9.0 (12.9) 5.3 (8.2) 9.2 (13.7)
Current smokers (%) 39.6b 31.2b 29.4 25.1
Attacks of wheezing or dyspnoea last
year (%)
52.6b 40.4 42.5 35.6
Chronic bronchitis (%)y 12.4a 10.8 9.2 10.9
Asthma diagnosis (%)z 41.1 42.3 37.9 36.8
Emphysema/chronic bronchitis (%)z 15.0a 17.9 11.4 16.1
Use of ICS last 6 months (%) 22.1 28.9 23.2 30.9
Current or past use of OCS for
respiratory disease (%)
9.4 10.2 11.1a 9.2
Bone mineral density (BMD) (mg/cm2)y
Mean distal BMD (SD) 437.1 (79.5) 560.3 (69.4) 443.9 (69.4)a 561.4 (66.2)
Mean ultradistal BMD (SD) 341.9 (78.4) 477.4 (76.0) 349.9 (70.6)a 475.3 (72.7)
bpo0.01, apo0.05 for the comparisons (independent t-test and w2-test) between participants lost and met to follow-up stratified by
sex.
Physical activity score, expressed as sum of hours with light and hard physical activity at leisure time.
ySelf-reported daily cough with phlegm at least 3 months a year during the last 2 yr.
zDiagnosis given by a medical doctor.
yStandardised measurements according to European Forearm Phantom.
Inhaled steroids and forearm bone mineral density 1747Including statistically significant contributing covariates
in the models did, to some extent, reduce the strength of
the association between ICS use and estimated loss of BMD,
but the negative associations between use of ICS and bone
loss were still significant (Table 4).
Restricting the analyses to those with respiratory symp-
toms and/or use of CS (levels II and III), using level II as
reference, revealed the same pattern. The difference in
yearly loss of distal BMD between users of ICS both at
baseline and at follow-up, and the level II reference group,
were 0.66mg/cm2 (p ¼ 0.19) and 1.84mg/cm2 (po0.01) for
women and men, respectively. Excluding those who
reported ever use of OCS from the analyses did not change
between-group differences significantly.
Use of estrogen had a positive effect on BMD, but
stratifying women according to estrogen use or not did not
significantly change the associations between ICS use and
BMD. Tobacco smoking had a negative effect on BMD.
Stratifying according to smoking history confirmed differ-
ences in bone loss between users of ICS at both measure-
ments and the reference group (level I), with po0.001,
p ¼ 0.035 and 0.01 for never smokers, ex-smokers, and
current smokers, respectively.
The fully adjusted yearly loss during follow-up of distal
and ultradistal BMD in the CS-naı¨ve subjects without
respiratory symptoms was 2.26 and 2.40mg/cm2 in women
and 1.92 and 2.28mg/cm2 in men. Corresponding values forusers of ICS at both measurements were 3.14 and 2.72
mg/cm2 in women and 3.76 and 3.43mg/cm2 in men
(Table 4). Calculated as SD derived from all participants
stratified by sex, the increase in yearly loss was equivalent
to 0.013 and 0.005 SD of distal and ultradistal BMD in
women, versus 0.028 and 0.016 SD in men.
In linear regression analyses with yearly loss in distal BMD
as dependent variables, stratification by age groups 20–44,
45–69, 70+ years, showed increasing b-coefficients for
current versus no ICS use at follow-up in men (1.15, 1.45,
and 2.49, respectively (all po0.01)), with a similar pattern
for ultradistal BMD (all po0.05). Corresponding pattern by
age was not found in women. Inclusion of OCS use in the
models did not change these results.
Among ICS users at both measurements, stratifying
according to follow-up doses into low (50–400 mg), medium
(500–800 mg), and high (X900 mg), revealed no difference by
dose in adjusted yearly change of distal BMD in women,
whilst men in the highest dose level had slightly higher
adjusted loss compared to the two other levels (5.90 versus
4.51 and 4.39mg/cm2), but the difference was not
statistically significant. A similar pattern was found for
ultradistal BMD. These patterns were not significantly
changed when FEV1% predicted was included in the models.
Corresponding comparisons between different categories
of duration or cumulative dose of ICS use revealed no
differences in yearly loss of BMD in either sex.
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Table 2 Use of inhaled corticosteroids (ICS) and oral corticosteroids (OCS) at baseline 1995–97 (BL) and at follow-up (FU),
2001, among subjects with current use of ICS at BL only, at FU only, and at both measurements.
At baseline At follow-up
Current ICS at BL only Current ICS at BL and
FU
Current ICS at FU only Current ICS at BL and
FU
n ¼ 528 n ¼ 153 n ¼ 528 n ¼ 196
ICS use
Mean dose mg (SD) 532 (355) 660 (435) 600 (373) 736 (466)
Dose category n (%)
50–400 mg 96 (62.8) 246 (46.6) 77 (39.3) 171 (32.4)
500–800 mg 42 (27.5) 202 (38.3) 88 (44.9) 232 (43.9)
900–1200 mg 7 (4.6) 37 (7.0) 17 (8.7) 66 (12.5)
1200+mg 8 (5.2) 43 (8.1) 12 (6.1) 55 (10.4)
Duration of use, n (%)
o12 months 60 (39.5) 68 (12.9) 19(9.7) 4 (0.8)
1–4.9 yr 45 (29.6) 220 (41.8) 58 (29.6) 42 (8.0)
X5 yr 47 (30.9) 238 (45.1) 107 (54.6) 482 (91.3)
Type used last 6 months, n (%)
Beclomethasone DP 26 (17.8) 75 (14.2) 20 (10.2) 79 (15.0)
Budesonide 118 (76.0) 425 (80.5) 109 (55.6) 390 (73.9)
Fluticasone P 9 (5.9) 28 (5.3) 86 (46.2) 172 (32.6)
OCS for asthma, n (%)
Ever use 30 (19.6) 196 (37.1) 62 (33.3) 237 (47.7)
Courses last 2 yr 19 (13.0) 115 (21.0) 39 (19.9) 147 (27.8)
Use 46 months 10 (6.6) 36 (6.4) 9 (4.6) 43 (8.1)
Use is reported as mean dose, type of steroid and duration of use.
At follow-up more than 100% in reported use of different ICS due to use of more than one type during the last 6 months.
A. Langhammer et al.1748Discussion
We found higher yearly loss of forearm BMD in ICS users
compared to CS-naı¨ve subjects, and a relatively and
absolutely greater effect in men than in women. Indepen-
dent of sex, bronchial obstruction was an independent risk
factor for increased bone loss.
The strength of the present study is the sample size and the
inclusion of both sexes aged 20–80 years recruited from an
unselected population. Even if site of measurement of
outcome (BMD) and exposure data on CS use might be
discussed, this study should add important knowledge regard-
ing effects of disease and CS use on BMD on a population level.Selection and participation
A non-responder study did not indicate a selection bias at
baseline.9 At follow-up a certain healthy survivor effect was
found, especially in women, but this might be outweighed
by use of higher ICS doses and more OCS courses among
those participating twice compared to those participating
once. Increased travel distance at follow-up for inhabitants
in the smaller municipalities (both coastal and inland)
probably was the main reason for low participation rates
especially in these areas, but this should not bias the results.Sites of measurement
Measurement of the hip is considered as the gold standard
for bone densitometry because of its predictive value for hip
fractures and better standardisation for the diagnosis of
osteoporosis. Further BMD of trabecular bone at the spine
and hip is more sensitive to CS effects than other sites.7,13
Forearm BMD measurements do, however, predict any
fracture in women in other sites as well,8 and may even
have a stronger association with male fragility fractures.14
Limited amount of surrounding tissue at the forearm
contributes to an accuracy error as low as 2% compared to
8–10% in spine measurements,15 and important for prospec-
tive studies, there is a precision error as low as 1%.16 The
forearm represents mainly cortical (distal site) and trabe-
cular (ultradistal site) bone. Corresponding differences in
metabolic effects as found between cortical and trabecular
bone in the spine and at the hip, are, however, not found in
the forearm,17 probably because of less haematopoietic
marrow at these sites.Corticosteroid exposure data
The data collection was performed at baseline and follow-
up. CS exposure was retrospectively self-reported, and some
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Inhaled steroids and forearm bone mineral density 1749non-differential misclassification of ICS exposure may con-
fine the study’s power to reveal a potential dose–response
relationship. However, being aware of the low compliance
with inhaled medications, self-reported current use of ICS
might reflect the true use as well as prescription data. Even
in motivated participants of a prospective study, weight
control of devices revealed that only half of the participants
could be classified as good compliers.18 In real-life studies,
the ICS doses actually being used varies, and in the present
study 40–50% of participants used the same dose category
(low, moderate, high) at follow-up compared to baseline.
The choice of which dose to include in the analyses might be
discussed. The results were consistent in analyses using log
current dose at follow-up and log mean dose at the two
measurements. As studies have indicated that the CS effect
on bone is reversible,19 the current dose at follow-up was
selected. As the population is sceptical of the use of OCS
there is no reason to fear lack of validity of self-reported
OCS use. However, inclusion of questions regarding OCS use
during the 3 months prior to follow-up might have given
more optimal adjustment for effects caused by OCS use.
Confounders
Like most observational studies, we cannot rule out residual
confounding especially by disease severity and lifestyle
factors.20 Patients with obstructive lung disease in need of
CS treatment are also characterised by other factors
influencing BMD, like tobacco smoking, physical inactivity
and ageing, in addition to a potential catabolic effect on
bone because of systemic effects of COPD itself.21 Variance
analyses might be biased by different distributions of
confounders in the groups being compared, but stratified
analyses showed consistency of the results. Physical activity
did not turn out to be a significant covariate in the present
study. This should be explained by the site of measurement.
The non-dominant forearm, not being part of the weight-
bearing skeleton, is influenced by physical activity to a very
limited degree.
A real CS effect could be estimated if CS users and CS-
naı¨ve subjects had similar disease severity. This, however, is
not possible with a low threshold for introducing ICS in the
treatment of obstructing lung diseases during the last few
decades in Norway.
Comparisons with other studies
Conflicting results have been reported regarding ICS effect
on bone. Some studies have reported a dose–response
relationship between ICS use and BMD,22,23 which might
indicate a causal effect, whilst others have not confirmed
this.
A prospective study of postmenopausal women also
measuring forearm BMD, did not find any loss in BMD
associated with a mean ICS exposure of 8.2 years.24 We
have, from baseline data, previously reported that com-
pared to ICS-naı¨ve subjects, the mean distal BMD was 2.1%
lower in current users of only inhaled CS, and 7.7% lower in
case of concomitant use of OCS for more than 6 months.10
The present study has revealed a corresponding greater
adjusted yearly loss in BMD in ICS users compared to
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A. Langhammer et al.1750CS-naı¨ve subjects at mean dose levels, similar to results
reported by Richy et al.25 Less reduction in BMD than
reported by others23,26 might reflect site-specific differ-
ences in CS influence.13
Meta-analyses increase the power, but different inclusion
criteria might explain conflicting results even among these.
A Cochrane review found no effect on BMD or vertebral
fractures of 2–3 years’ use of ICS at conventional doses.22
Correspondingly, Halpern et al.27 did not find significant
association between ICS use and lumbar or hip BMD, and
Leone et al.6 found no association between ICS use and
reduced BMD in children and adults with asthma, although
they concluded that use of high-dose ICSs for many years in
adults could result in clinically important effects on BMD.
Another meta-analysis, including the Lung Health Study,
found 4.1% lower lumbar spine BMD associated with ICS use,
but statistical significance was not achieved.28 Richy et
al.,25 however, found that ICS use was associated with
reduced BMD at the lumbar spine, hip, and femoral neck.
In the Lung Health Study, a dose–response effect of
triamcinolone acetonide (TAA) was found on BMD at the total
hip and trochanter in premenopausal women,26 whilst no
effect was found on the spine or femoral neck representing
mainly trabecular bone. Use of 1000mg TAA was associated
with 0.5% ( ¼ 0.05 SD) increased loss of total hip BMD. TAA hasa relatively narrow therapeutic index and exerts a greater
systemic effect than other ICSs.25,29 The results, however,
were in crude agreement with a study including other ICSs
(mainly BDP), reporting a decrease in BMD of 0.16 SD at the
lumbar spine for each doubling of the cumulative ICS dose.23
Assessments of potential confounders like lung function,
physical activity, diet, and use of OCS have variably and by
varying quality been included in the studies. Register studies
are important contributions to current knowledge, but have
not included lifestyle data and might, in a limited degree,
adjust for disease severity.4,5,30,31
The hard endpoint on studies of CS effects on bone is
fractures. The present study had no power to detect such
effects, but interestingly revealed a 70% increased risk for
fractures (not validated) in patients with obstructive lung
disease (data not shown). Studies on ICS use and fracture
risk have not given conclusive results, the results varying
from no effect to dose–response relationship, mainly in the
use of high ICS doses.4,5,30,31Clinical significance of results
A reduction in BMD of 1 SD has been associated with the
doubling of fracture risk in women.8 The present finding of a
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.
Inhaled steroids and forearm bone mineral density 1751yearly increased loss of distal BMD of 0.013 SD in women and
0.028 SD in men, associated with the use of ICS, indicates a
very limited clinical significant increase in fracture risk. Use
of fixed combinations of ICS and long-acting b2-agonists has
led to use of lower ICS doses in asthma patients. However,
severe COPD patients already at risk for osteoporosis
because of lifestyle are still recommended use of high ICS
doses. This, together with CS acting as an independent risk
factor of fracture,32 necessitates considering prophylactic
measures to protect the skeleton.
Our finding of a greater effect associated with ICS use on
BMD in men compared to women might reflect higher
susceptibility in male bones for CS, but could also reflect
differences in disease severity between sexes. Breath-
lessness might cause a greater reduction in the level of
physical activity in men compared to women, but measure-
ment of a not weight-bearing and less active part of the
body should limit such an effect. Otherwise, women, as
opposed to men, at risk for osteoporosis previously had
treatment opportunities like estrogen, but this has been
adjusted for in the analyses.Conclusions
Users of ICS have higher loss of BMD at the forearm
compared to never users. The loss of BMD, however, was
small and should be of minor clinical significance in most
patients using low to moderate doses of ICS.Acknowledgements
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